Search

This comprehensive review aims to explore the future potential of nasopulmonary drug delivery systems for the administration of drugs through the nasal route. Nasal drug delivery has gained significant attention due to its numerous advantages, including rapid absorption, avoidance of first-pass metabolism, and non-invasive administration. This review provides an overview of the nasal anatomy and physiology, highlighting the factors influencing drug absorption and bioavailability. Additionally, it discusses the various types of nasopulmonary drug delivery systems, such as nasal sprays, powders, and gels, along with their advantages and limitations. Furthermore, the review delves into the challenges associated with nasal drug delivery, including mucociliary clearance, nasal irritation, and formulation issues. The potential applications of nasopulmonary drug delivery systems in the treatment of various diseases, such as allergies, respiratory disorders, and systemic conditions, are also discussed. Finally, the review concludes with an outlook on the future prospects of nasopulmonary drug delivery systems, emphasising the need for further research and development to optimise their efficacy and safety. Keywords: nasal pulmonary; nasal spray; nasal mucosa; gels; drops; nasal approaches; nasal route; nasal delivery.

The present study aimed to develop and evaluate thermoreversible in situ nasal gel containing Curcumin nanoparticles. Curcumin nanoparticles were prepared by the ionic gelation method. These formulations were evaluated for entrapment efficiency, particle size, zeta potential, and In vitro drug release. Particle size and zeta potential of F1 formulation were found to be 299 nm, 0.1 mV, and entrapment efficiency was found to be87.2%. From the formulations, F1 shows maximum amount of drug released in a sustained manner for a prolonged period time. Hence F1formulation was selected as optimized and further used for thermoreversible in situ nasal gel by using 2×2 factorial designs. The thermoreversible nasal gel was evaluated for the gelation temperature (33˚C), viscosity (10550cps) and spreadability (17.29±0.3 gm*cm/sec). Further, the prepared gel (F1G3) was evaluated for ex vivo permeation study for12 hours and it shows maximum amount of drug release in a controlled manner. The % CDR of thermoreversible in situ gel formulation F1G3 was found to be 86.27% which follow the Higuchi model. The 'n' value of the formulation was found to be more than 0.5. This indicate that the release approximates the non-fickain diffusion mechanism. Keywords: Curcumin nanoparticles, Carbopol 934, PF127, Thermoreversible in situ gel, Cold method, Nasal delivery.

The present study aimed to develop and evaluate thermoreversible in situ nasal gel containing Curcumin nanoparticles. Curcumin nanoparticles were prepared by the ionic gelation method. These formulations were evaluated for entrapment efficiency, particle size, zeta potential, and In vitro drug release. Particle size and zeta potential of F1 formulation were found to be 299 nm, 0.1 mV, and entrapment efficiency was found to be87.2%. From the formulations, F1 shows maximum amount of drug released in a sustained manner for a prolonged period time. Hence F1formulation was selected as optimized and further used for thermoreversible in situ nasal gel by using 2×2 factorial designs. The thermoreversible nasal gel was evaluated for the gelation temperature (33˚C), viscosity (10550cps) and spreadability (17.29±0.3 gm*cm/sec). Further, the prepared gel (F1G3) was evaluated for ex vivo permeation study for12 hours and it shows maximum amount of drug release in a controlled manner. The % CDR of thermoreversible in situ gel formulation F1G3 was found to be 86.27% which follow the Higuchi model. The 'n' value of the formulation was found to be more than 0.5. This indicate that the release approximates the non-fickain diffusion mechanism. Keywords: Curcumin nanoparticles, Carbopol 934, PF127, Thermoreversible in situ gel, Cold method, Nasal delivery.

This comprehensive review aims to explore the future potential of nasopulmonary drug delivery systems for the administration of drugs through the nasal route. Nasal drug delivery has gained significant attention due to its numerous advantages, including rapid absorption, avoidance of first-pass metabolism, and non-invasive administration. This review provides an overview of the nasal anatomy and physiology, highlighting the factors influencing drug absorption and bioavailability. Additionally, it discusses the various types of nasopulmonary drug delivery systems, such as nasal sprays, powders, and gels, along with their advantages and limitations. Furthermore, the review delves into the challenges associated with nasal drug delivery, including mucociliary clearance, nasal irritation, and formulation issues. The potential applications of nasopulmonary drug delivery systems in the treatment of various diseases, such as allergies, respiratory disorders, and systemic conditions, are also discussed. Finally, the review concludes with an outlook on the future prospects of nasopulmonary drug delivery systems, emphasising the need for further research and development to optimise their efficacy and safety. Keywords: nasal pulmonary; nasal spray; nasal mucosa; gels; drops; nasal approaches; nasal route; nasal delivery.

Nasal delivery offers many benefits over other conventional routes of delivery (e.g. oral or intravenous administration). Benefits include, among others, a fast onset of action, non-invasiveness and direct access to the central nervous system. The nasal cavity is not only limited to local application (e.g. rhinosinusitis) but can also provide direct access to other sites in the body (e.g. the central nervous system or systemic circulation). However, both the anatomy and the physiology of the nose impose their own limitations, such as a small volume for delivery or rapid mucociliary clearance. To meet nasal-specific criteria, the formulator has to complete a plethora of tests, in vitro and ex vivo, to assess the efficacy and tolerance of a new drug-delivery system. Moreover, depending on the desired therapeutic effect, the delivery of the drug should target a specific pathway that could potentially be achieved through a modified release of this drug. Therefore, this review focuses on specific techniques that should be performed when a nasal formulation is developed. The review covers both the tests recommended by regulatory agencies (e.g. the Food and Drug Administration) and other complementary experiments frequently performed in the field., SCOPUS: re.j, info:eu-repo/semantics/published

Present review highlights the potential of nasal mucosa as an administration route for targeting the central nervous system, the brain. Targeted drug delivery seeks to concentrate the medication in the tissues of interest while reducing the relative concentration of medication in the remaining tissues. Thus improving efficacy of the drug and reducing side effects. The nasal mucosa when compared to other mucousmembranes is easily accessible and provides a practical entrance portal for small and large molecules.Intranasal administration offers rapid onset of action, no first-pass effect, no gastrointestinal degradationor lung toxicity and non-invasiveness application and also improves bioavailability. It is thought thatolfactory route of drug transport, by pass the blood-brain barrier and allows the direct transport of drugfrom the nose to the brain. This review provides an overview of strategies to improve the drug delivery to brain via nasal mucosa and recent advances in this field.

Present review highlights the potential of nasal mucosa as an administration route for targeting the central nervous system, the brain. Targeted drug delivery seeks to concentrate the medication in the tissues of interest while reducing the relative concentration of medication in the remaining tissues. Thus improving efficacy of the drug and reducing side effects. The nasal mucosa when compared to other mucousmembranes is easily accessible and provides a practical entrance portal for small and large molecules.Intranasal administration offers rapid onset of action, no first-pass effect, no gastrointestinal degradationor lung toxicity and non-invasiveness application and also improves bioavailability. It is thought thatolfactory route of drug transport, by pass the blood-brain barrier and allows the direct transport of drugfrom the nose to the brain. This review provides an overview of strategies to improve the drug delivery to brain via nasal mucosa and recent advances in this field.

Present review highlights the potential of nasal mucosa as an administration route for targeting the central nervous system, the brain. Targeted drug delivery seeks to concentrate the medication in the tissues of interest while reducing the relative concentration of medication in the remaining tissues. Thus improving efficacy of the drug and reducing side effects. The nasal mucosa when compared to other mucousmembranes is easily accessible and provides a practical entrance portal for small and large molecules.Intranasal administration offers rapid onset of action, no first-pass effect, no gastrointestinal degradationor lung toxicity and non-invasiveness application and also improves bioavailability. It is thought thatolfactory route of drug transport, by pass the blood-brain barrier and allows the direct transport of drugfrom the nose to the brain. This review provides an overview of strategies to improve the drug delivery to brain via nasal mucosa and recent advances in this field.